Skip to main content
BNGO logo

BNGO · Bionano Genomics, Inc. · Documents

Track BNGO — free
$0.95 -0.05 (-5.30%) Play latest call Q3 2026 earnings call transcript
Market Cap
$13.99M
Shares
13.99M
Volume · Nov 16 165.45K Avg daily vol (3M) 965.62K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $28.51M down 7.4% 10-K filed Mar 23, 2026 Quarterly report New FY2026 Q3 Revenue $8.28M up 12.3% 10-Q filed Nov 10, 2026 Latest results New Revenue rises 12% and guidance stays $31 to $33 million 8-K filed Nov 10, 2026 Earnings call New Q3 2026 earnings call Held Nov 10, 2026
2026
Nov 10
Earnings call
Q3 revenue rises 12%; flow-cell sales hit record 9,870

BioNano reported Q3 2026 revenue of $8.3 million, up 12%, and record flow-cell sales of 9,870 units, up 18%. Adjusted gross margin reached 48%, and full-year 2026 revenue guidance remained $31 million to $33 million.

5 source passages
BioNano delivered a strong third quarter. Q3 2026 flow cells sold were up 18% year-over-year at 9,870 units, a record for any quarter. Revenue for the third quarter of 2026 was $8.3 million, up 12% compared to Q3 2025. adjusted gross margin for the third quarter of 2026 was 48% compared to 46% in Q3 2025. for the full year 2026, we are reiterating our revenue guidance of $31 million to $33 million Open the document at this passage
Nov 10
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue grows, but substantial doubt raises near-term financing risk

Bionano Genomics reported revenue of $23.1 million, up 13%, and a $22.2 million net loss for the nine months ended September 30, 2026. It faces substantial doubt about going concern and expects additional capital in the very near term.

Revenue $8.28M ▲ 12.3% Net loss $6.45M Diluted EPS -$0.54
Read from the MD&A section
5 source passages
Unless the context requires otherwise, references to “we,” “us,” and “our” refer to Bionano Genomics, Inc. and its subsidiaries or, as the context may require, Bionano Genomics, Inc. only. Total revenue increased by $2.6 million, or 13% to $23.1 million for the nine months ended September 30, 2026, as compared to $20.6 million for the same period in 2025, driven primarily by an increase in instrument, consumables, service and other revenue partially offset by a decrease in software revenue. Our net loss was $6.5 million and $22.2 million for the three and nine months ended September 30, 2026, respectively. Accordingly, based on recurring losses from operations incurred since inception, the expectation of continued operating losses, and the need to raise additional capital to finance our future operations, we determined that there is substantial doubt about our ability to continue as a going concern within 12 months after the date that the financial statements included in this Quarterly Report are issued. Based on our current business plans, we will continue to require additional capital in the very near term to fund our operating expenses and capital expenditure requirements, or we may need to further curtail or cease operations and seek protection by filing a voluntary petition for relief under the United States Bankruptcy Code. Open the document at this passage
Nov 10
Current report 8-K
Revenue rises 12% and guidance stays $31 to $33 million

Bionano Genomics reported third-quarter revenue of $8.3 million, up 12% from $7.4 million, and gross margin of 48%, up from 46%. It reiterated full year 2026 revenue guidance of $31 to $33 million.

Financial results
4 source passages
Reported total revenue of $8.3 million, representing an increase of 12% from $7.4 million in the third quarter of 2025. Generated gross margin of 48%, as compared to 46% for the third quarter of 2025. We anticipate the following results for the full year 2026: Reiterate full year 2026 revenue guidance in the range of $31 to $33 million. Open the document at this passage
Nov 2
Registration statement S-3/A
Registration statement

Bionano Genomics, Inc. established a replacement shelf registration for up to $400,000,000 and disclosed an additional $3,941,645.77 of securities sold under its prior registration statement.

Read from the first part of this long document
Oct 27
Registration statement S-1
Registration statement

Bionano Genomics, Inc. is registering up to 1,332,632 shares issuable upon exercise of outstanding warrants, replacing an expiring registration statement so warrant exercises remain covered. Full exercise would generate approximately $90 million for general corporate purposes.

Read from the first part of this long document
Aug 10
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $8.17M ▲ 21.4% Net loss $7.42M Diluted EPS -$0.64
Jun 24
Current report 8-K
Other events AI summary on its way
May 28
Current report 8-K
Other events AI summary on its way
May 13
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $6.69M ▲ 3.6% Net loss $8.3M Diluted EPS -$0.76
Mar 23
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $28.51M ▼ 7.4% Net loss $26.4M Diluted EPS -$4.85
2025
Mar 31
Annual report 10-K FY2024, ended Dec 31
Annual report for FY2024
Revenue $30.78M ▼ 14.8% Net loss $112.02M Diluted EPS -$88.13
Showing 1–50 of 215 documents
Key facts CIK 1411690 CUSIP 09075F404 13F (30d) 43 filings 25 filers Visit website Investor relations